Sydney Pharmacy School, The University of Sydney, Sydney, NSW, 2006, Australia.
Charles Perkins Centre, The University of Sydney, Sydney, NSW, 2006, Australia.
J Cancer Res Clin Oncol. 2018 Aug;144(8):1561-1568. doi: 10.1007/s00432-018-2669-6. Epub 2018 May 22.
Platinum drugs have been in use in cancer treatment for more than 40 years, but little is known about the pattern of their use. The aim of this study was to examine the patterns of platinum drug use, with a secondary aim to describe the occurrence of dose reductions.
A retrospective analysis was conducted of oncology pharmacy dispensing records from a single hospital in Australia. Data related to drug choice, regimen and dose reductions were included in this study if the patient had received their last round of chemotherapy between November 2014 and July 2015.
Of the 156 patients included in the study, 46% were dispensed a platinum drug during their treatment. The most commonly dispensed drugs were cisplatin (40%), carboplatin (40%) and oxaliplatin (15%), while some patients (5%) received more than one platinum drug. Dose reductions were more common in patients who were treated with a platinum drug (73%) compared with patients treated with non-platinum drugs (55%). The most common reason for a dose reduction was cytopenia.
The findings suggest that platinum drugs remain one of the most commonly dispensed drugs to treat cancer patients and most patients receive a dose reduction during treatment.
铂类药物在癌症治疗中已经使用了 40 多年,但人们对其使用模式知之甚少。本研究旨在研究铂类药物的使用模式,并进一步描述剂量减少的发生情况。
对澳大利亚一家医院的肿瘤药房配药记录进行回顾性分析。本研究纳入了患者在 2014 年 11 月至 2015 年 7 月期间接受最后一轮化疗的药物选择、方案和剂量减少的数据。
在纳入研究的 156 名患者中,46%的患者在治疗期间接受了铂类药物治疗。最常使用的药物为顺铂(40%)、卡铂(40%)和奥沙利铂(15%),而一些患者(5%)接受了一种以上的铂类药物。与接受非铂类药物治疗的患者(55%)相比,接受铂类药物治疗的患者(73%)更常见剂量减少。剂量减少的最常见原因是细胞减少症。
这些发现表明,铂类药物仍然是治疗癌症患者最常用的药物之一,大多数患者在治疗过程中会减少剂量。